The FluCide-I studies will be conducted “in a world-renowned institution in Boston,” says Anil W. Diwan, PhD, president of Westhaven, CT-based NanoViricides. They are scheduled to start this week, with the first phase slated to last four to six weeks. “Hopefully, we will have sufficient success that tells us what changes need to be made, and by the second or third time around we’ll be there,”
says Diwan. “Then, we simply reset the nanoviricide 's target to H5N1, the bird flu virus.
“We want to create the first viricide”.